Literature DB >> 17906660

Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma.

Michelle L Gervais1, Pauline C Henry, Arthy Saravanan, T Nadine Burry, Brenda L Gallie, Michael A S Jewett, Richard P Hill, Andrew J Evans, Michael Ohh.   

Abstract

The loss of functional von Hippel-Lindau (VHL) tumor suppressor gene is associated with the development of clear-cell renal cell carcinoma (CC-RCC). Recently, VHL was shown to promote the transcription of E-cadherin, an adhesion molecule whose expression is inversely correlated with the aggressive phenotype of numerous epithelial cancers. Here, we performed immunohistochemistry on CC-RCC tissue microarrays to determine the prognostic value of E-cadherin and VHL with respect to Fuhrman grade and clinical prognosis. Low Fuhrman grade and good prognosis associated with positive VHL and E-cadherin immunoreactivity, whereas poor prognosis and high-grade tumors associated with a lack of E-cadherin and lower frequency of VHL staining. A significant portion of CC-RCC with positive VHL immunostaining correlated with nuclear localization of C-terminally cleaved E-cadherin. DNA sequencing revealed in a majority of nuclear E-cadherin-positive CC-RCC, subtle point mutations, deletions and insertions in VHL. Furthermore, nuclear E-cadherin was not observed in chromophobe or papillary RCC, as well as matched normal kidney tissue. In addition, nuclear E-cadherin localization was recapitulated in CC-RCC xenografts devoid of functional VHL or reconstituted with synthetic mutant VHL grown in SCID mice. These findings provide the first evidence of aberrant nuclear localization of E-cadherin in CC-RCC harboring VHL mutations, and suggest potential prognostic value of VHL and E-cadherin in CC-RCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906660     DOI: 10.1038/labinvest.3700684

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  13 in total

Review 1.  E-cadherin's dark side: possible role in tumor progression.

Authors:  Fausto J Rodriguez; Laura J Lewis-Tuffin; Panos Z Anastasiadis
Journal:  Biochim Biophys Acta       Date:  2012-03-13

2.  MicroRNA-720 Regulates E-cadherin-αE-catenin Complex and Promotes Renal Cell Carcinoma.

Authors:  Nadeem S Bhat; Melissa Colden; Altaf A Dar; Sharanjot Saini; Prerna Arora; Varahram Shahryari; Soichiro Yamamura; Yuichiro Tanaka; Taku Kato; Shahana Majid; Rajvir Dahiya
Journal:  Mol Cancer Ther       Date:  2017-08-11       Impact factor: 6.261

3.  Exon 11 skipping of E-cadherin RNA downregulates its expression in head and neck cancer cells.

Authors:  Sanjai Sharma; Wei Liao; Xiaofeng Zhou; David T W Wong; Alan Lichtenstein
Journal:  Mol Cancer Ther       Date:  2011-07-15       Impact factor: 6.261

4.  Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.

Authors:  Alison C Young; Rachel A Craven; Dena Cohen; Claire Taylor; Christopher Booth; Patricia Harnden; David A Cairns; Dewi Astuti; Walter Gregory; Eamonn R Maher; Margaret A Knowles; Adrian Joyce; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

5.  Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma.

Authors:  Hanna Ronkainen; Saila Kauppila; Pasi Hirvikoski; Markku H Vaarala
Journal:  J Exp Clin Cancer Res       Date:  2010-01-14

6.  Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Authors:  Andrew M Roberts; Ian R Watson; Andrew J Evans; David A Foster; Meredith S Irwin; Michael Ohh
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

7.  Altered expression of β-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma.

Authors:  Rahul Bhagat; C S Premalata; V Shilpa; V R Pallavi; G Ramesh; C R Vijay; Lakshmi Krishnamoorthy
Journal:  Tumour Biol       Date:  2013-04-19

Review 8.  The VHL tumor suppressor and HIF: insights from genetic studies in mice.

Authors:  P P Kapitsinou; V H Haase
Journal:  Cell Death Differ       Date:  2008-01-25       Impact factor: 15.828

9.  Development of flexible-heteroarotinoids for kidney cancer.

Authors:  Tongzu Liu; Chioniso Patience Masamha; Shylet Chengedza; K Darrell Berlin; Stan Lightfoot; Feng He; Doris Mangiaracina Benbrook
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

10.  Disseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone.

Authors:  Carolyn G Marsden; Mary Jo Wright; Latonya Carrier; Krzysztof Moroz; Brian G Rowan
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.